Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

Nature Genetics

Volumn 36, Issue 1, 2004, Pages 63-68

  Liu, Geng ^a   Parant, John M ^a   Lang, Gene ^a   Chau, Patty ^a   Chavez Reyes, Arturo ^a   El Naggar, Adel K ^a   Multani, Asha ^a   Chang, Sandy ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO ACID SUBSTITUTION; ANEUPLOIDY; ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; GENE MUTATION; GENE REPRESSION; GENETIC STABILITY; LYMPHOMA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SENESCENCE; SEQUENCE HOMOLOGY; THYMUS LYMPHOMA;

ANIMALS; APOPTOSIS; CELL CYCLE; CHROMOSOMAL INSTABILITY; GENES, P53; LYMPHOMA; MICE; MICE, MUTANT STRAINS; PLOIDIES;

ANIMALIA;

EID: 0346455759     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1282     Document Type: Article

References (30)

1. Ko, L.J. & Prives, C. p53: puzzle and paradigm. Genes Dev. 10, 1054-1072 (1996).
2. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
3. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature 408, 307-310 (2000).
4. Rowan, S. et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15, 827-838 (1996).
5. Ludwig, R.L., Bates, S. & Vousden, K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16, 4952-4960 (1996).
6. Deng, C., Zhang, P., Harper, J.W., Elledge, S.J. & Leder, P., Mice lacking p21ClP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
7. el-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
8. Lowe, S.W., Jacks, T., Housman, D.E. & Ruley, H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA 91, 2026-2030 (1994).
9. Soengas, M.S. et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156-159 (1999).
10. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
11. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments]. Nature 362, 849-852 (1993).
12. Lee, Y., Chong, M.J. & McKinnon, P.J. Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J. Neurosci. 21, 6687-6693 (2001).
13. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
14. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
15. Nacht, M. & Jacks, T. V(D)J recombination is not required for the development of lymphoma in Trp53-deficient mice. Cell Growth Differ. 9, 131-138 (1998).
16. Harvey, M. et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457-2467 (1993).
17. Venkatachalam, S. et al. Retention of wild-type Trp53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657-4667(1998).
18. Liao, M.J. et al. No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol. Cell. Biol. 18, 3495-3501 (1998).
19. Hundley, J.E. et al. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53 Mol. Cell. Biol. 17, 723-731 (1997).
20. Tarapore, P. & Fukasawa, K. Loss of p53 and centrosome hyperamplification. Oncogene 21, 6234-6240 (2002).
21. Tlsty, T.D. Regulation of genomic instability in preneoplastic cells. Cancer Surv. 28, 217-224 (1996).
22. Donehower, L.A. Genetic instability in animal tumorigenesis models. Cancer Surv. 29, 329-352(1997).
23. Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instability in colorectal cancers. Nature 386, 623-627 (1997).
24. Tarapore, P., Horn, H.F., Tokuyama, Y. & Fukasawa, K. Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway. Oncogene 20, 3173-3184(2001).
25. Schmitt, C.A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298(2002).
26. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
27. Kinzler, K.W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
28. Liu, G. et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. USA 97, 4174-4179 (2000).
29. Lakso, M. et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl. Acad. Sci. USA 89, 6232-6236 (1992).
30. Kapoor, M. & Lozano, G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. USA 95, 2834-2837 (1998).